PubMed Health⌕ Search

Biomedical subjects

F Gobbi

Publications and source records attributed to F Gobbi.

32 records · Page 2Linked to original sources
PubMedDate not supplied

Chronic neutrophilic leukemia (CNL) with karyotypic abnormalities associated with plasma cell dyscrasia: a case report.

A case of chronic neutrophilic leukemia (CNL), a rare myeloproliferative syndrome associated with monoclonal gammopathy of uncertain significance (MGUS-Type IgGk), is reported. Karyotypic study, carried out on bone marrow, excluded Philadelphia-pos. chronic myeloid leukemia (CML) and showed Y loss (45 XO). Only a few cases of CNL with paraproteinemia have been reported, but no case of associated karyotypic abnormalities and paraproteinemia has so far been described.

Aged↗
PubMedDate not supplied

[The preoperative staging of rectal cancer with endorectal echography].

The authors stress the value of the routine use of endorectal US for the preoperative staging of rectal cancer. This method accurately demonstrates the exact level of the lesion, the degree of circumferential invasion, the depth of local involvement and the extent of eventual spread beyond the rectal wall, the invasion of the surrounding structures and the presence of enlarged perirectal lymph nodes. A hundred and forty-one patients with rectal carcinoma located 3-16 cm from the ano-cutaneous line were examined with endorectal US preoperatively; a comparison was made between US findings and pathological data, so that a correlation could be made between US (uT) and histologic (pT) findings. A radial probe and a 7-MHz transducer were employed. Our results show US accuracy to be 93.6% with only 4 cases of understaging and 5 of overstaging. A hundred and twenty-nine patients who had undergone major surgery were also studied to evaluate US accuracy in lymph node detection: in 110 cases the actual lymph node status was correctly demonstrated; US diagnostic accuracy was 85.3% with 16 false positives and 3 false negatives. The correct evaluation of the actual local tumor spread, as demonstrated by endoluminal US, allows the choice of the correct treatment, together with a personalized therapeutic schedule, to reduce the incidence of local recurrences and to save, whenever possible, sphincter functionality.

Adult↗
PubMedDate not supplied

[Hashimoto's thyroiditis, idiopathic thrombocytopenic purpura (Werlhof's disease) and Steinert's dystrophia myotonica. A clinical case].

The authors report a rare association: Hashimoto's thyroiditis, thrombocytopenic idiopathic purpura (Werlhof's disease) and Steinert's myotonic dystrophia. The authors outline the fingerprints of each disease, report particular syndromes and compare that association to data of partially reviewed literature. They suppose a suggestive pathogenetic connection among these diseases, due to the coexistence of altered genetic, endocrine and autoimmune factors and consequently impaired cell membrane permeability.

Adult↗
PubMedDate not supplied

Cost/benefit relationship in 46 cases of myelodysplastic syndrome (RAEB and RAEB-T): a quality assurance analysis in clinical haematology.

BACKGROUND: Myelodysplastic Syndromes (MDS) are common and severe haematologic diseases. Clinicians still have no standard therapies surely able to obtain a better result in the different MDS (RAEB and RAEB-t in particular). Moreover, the costs due to the specific drug, to its clinical complications and to the days spent in hospital can be influenced by the chosen therapeutic regime. There are no published studies regarding a cost-benefit relationship of the different drugs commonly used today for MDS patients. PATIENTS AND METHODS: This retrospective study refers to 46 patients with RAEB or RAEB-t, followed in our Division from 1986 up to December 1992. The authors reviewed specific therapies (ARA-C vs other drugs, in particular), the costs supported by the National Health Service and the effects of the same therapies in terms of survival. The results have been worked out by statistical analysis. RESULTS: Some interesting data are presented in this study: chemotherapy does not improve survival and causes higher costs; the length of stay in hospital is not influenced by using chemotherapy or not; RAEB patients cause as high costs as RAEB-t ones. CONCLUSIONS: Although the study regards only a limited number of cases, it shows that the therapeutic efforts made so far in order to improve MDS patients' prognosis cannot be considered satisfying and their social cost is very high. Our report can be a useful starting-point for a QA analysis concerning the rational use of new drugs such as growth factors and interleukins.

Aged↗